Kyodo News: Meiji Group Pharmaceutical Company develops a new crown vaccine to say that side effects are very small adaptive to fear adverse reaction group

China Well -off Network, July 11. KM Biology Company, a subsidiary of the Meiji Group, Japan, said on the 6th that the clinical trials of the new crown vaccine developed by the development of the new crown vaccine show The proportion of adverse reactions is low. The company said that people who are worried about adverse reactions and are unwilling to vaccine will "become new options."

The Kyodo News Agency reported that KM Biology said that it was not only for adults, but also to promote clinical trials for children. Both vaccines will use a new emergency approval system to plan to apply for pharmaceutical approval from the government as soon as the end of September.

Clinical trial objects are 2,500 people over 18 years old who have not been vaccinated with new crown vaccines. The occurrence of adverse reactions is the same as that of seasonal influenza vaccines. The effectiveness of the virus has also been confirmed.

The company also carried out clinical trials on children under the age of 6 and under the age of 18, and it is reported that progress is smooth.

KM Biology is a vaccine for vaccines and is made of the same method such as Japanese encephalitis such as Japanese encephalitis. The company focused on obtaining pharmaceutical approval and has established a production system in the factory in Kumamoto Prefecture under the support of the government.

- END -